The protein expression levels of five TGF-β/Smad signaling biomarkers, such as TGF-β1, Smad2, p-smad2, Smad3, and p-smad3, were assessed in TNF-α-treated BPH-1 and WPMY-1 cells. This evidence concerns the gene SMAD2 and benign prostatic hyperplasia.